Evidence map›Paper›PMID 40733523›Full record

Observational studyViruses2025

Worsening of Controlled Attenuation Parameter and Metabolic Profile After HCV Cure in People with HIV as a Sign of Steatosis.

Alessia Siribelli, Sara Diotallevi, Laura Galli, Camilla Muccini, Giulia Morsica, Riccardo Lolatto, Tommaso Clemente, Emanuela Messina, Costanza Bertoni, Caterina Uberti-Foppa and 2 more

Abstract readObservational Study
In one paragraph

Observational study in Viruses, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Alessia SiribelliDepartment of Infectious Diseases, Vita-Salute San Raffaele University, 20132 Milan, Italy.ORCID 0009-0004-8251-6963
Sara DiotalleviUnit of Infectious Diseases, San Raffaele Scientific Institute, 20132 Milan, Italy.
Laura GalliUnit of Infectious Diseases, San Raffaele Scientific Institute, 20132 Milan, Italy.
Camilla MucciniUnit of Infectious Diseases, San Raffaele Scientific Institute, 20132 Milan, Italy.ORCID 0000-0002-0900-5639
Giulia MorsicaUnit of Infectious Diseases, San Raffaele Scientific Institute, 20132 Milan, Italy.ORCID 0000-0003-4891-5376
Riccardo LolattoUnit of Infectious Diseases, San Raffaele Scientific Institute, 20132 Milan, Italy.ORCID 0000-0002-2447-6498
Tommaso ClementeUnit of Infectious Diseases, San Raffaele Scientific Institute, 20132 Milan, Italy.ORCID 0000-0001-6548-3427
Emanuela MessinaUnit of Infectious Diseases, San Raffaele Scientific Institute, 20132 Milan, Italy.
Costanza BertoniDepartment of Infectious Diseases, Vita-Salute San Raffaele University, 20132 Milan, Italy.ORCID 0009-0000-6703-6276
Caterina Uberti-FoppaDepartment of Infectious Diseases, Vita-Salute San Raffaele University, 20132 Milan, Italy.
Antonella CastagnaDepartment of Infectious Diseases, Vita-Salute San Raffaele University, 20132 Milan, Italy.
Hamid HassonUnit of Infectious Diseases, San Raffaele Scientific Institute, 20132 Milan, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In HCV-coinfected people with HIV (PWH), there are still conflicting data regarding the long-term metabolic impact of HCV eradication. The aim of the study is to investigate long-term changes in controlled attenuation parameter (CAP) and metabolic profile after sustained virological response (SVR) post-direct acting antivirals (DAAs) in PWH. This is a retrospective observational study including individuals with HIV/HCV coinfection, followed as outpatients at San Raffaele Hospital, who achieved SVR post-DAAs. Individuals were assessed for metabolic parameters before and after the start of DAAs. Univariate and multivariate mixed linear models were calculated to estimate crude mean changes in CAP, metabolic parameters, and weight; slopes were reported with the corresponding 95% confidence intervals (95% CI). Overall, during a median follow-up of 4.02 years (interquartile range, IQR 3.04-4.80), the mean percent increase in CAP was 2.86/year (

Indexed as

Fatty LiverHepatitis CHepatitis C, ChronicHIV InfectionsMetabolomeAdultAntiviral AgentsCoinfectionFemaleHepacivirusHumansMaleMiddle AgedRetrospective StudiesSustained Virologic ResponseAntiviral AgentsCAPDAAsHCVHIVsteatosisSVR

Identifiers

PMID40733523
PMCPMC12299559

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.